HealthcarePapers
HealthcarePapers
21(1) January 2023
: 34-37.doi:10.12927/hcpap.2023.26998
Abstract
Canadian and foreign governments are struggling with determining whether to reimburse expensive drugs for rare diseases. The problem is that although insurers want to offer fair access to medicines for patients with rare diseases, the drugs are often priced far above normal cost-effectiveness thresholds. This leaves insurers with no tools to determine how much to pay. This article notes one reasonable standard: prices should not, in these circumstances, allow for profiteering by innovative companies.
Comments
Be the first to comment on this!
This article is for subscribers only. To view the entire article
Related Articles
Note: Please enter a display name. Your email address will not be publically displayed